Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

R. Nadal, A. Amin, D. M. Geynisman, M. H. Voss, M. Weinstock, J. Doyle, Z. Zhang, A. Viudez, E. R. Plimack, D. F. McDermott, R. Motzer, B. Rini, H. J. Hammers

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science